GHK-Cu

GHK is a tripeptide, glycine-histidine-lysine, found naturally in human plasma. Its defining property is that it binds copper(II) with an affinity in a specific and useful range: tight enough to hold the ion, loose enough to exchange it with albumin and with cellular copper-handling proteins. The copper complex, written GHK-Cu, is the form studied in nearly all of the biological literature and is what gives the material its distinctive blue color.

The reason a copper carrier is biologically interesting is that copper is required as a cofactor by a specific set of enzymes and is toxic when it circulates unbound. Free copper is redox active and participates in reactions that generate reactive oxygen species, so organisms keep essentially none of it free. Any molecule that can deliver copper to enzymes without releasing it into solution occupies a functionally important niche, and that is the position GHK is proposed to hold.

Research on this tripeptide spans more than five decades and covers copper coordination chemistry, fibroblast culture work on extracellular matrix protein synthesis, gene expression profiling, and rodent injury models, alongside a body of small human studies conducted on topical cosmetic formulations. Response BioLabs supplies GHK-Cu as a lyophilized powder for laboratory research use only.

GHK was identified in 1973 by Loren Pickart, then working on a question about tissue aging: why did human liver tissue from older donors behave differently in culture from tissue from younger donors. He reported that a low molecular weight factor present in the plasma of young donors changed the behavior of the older tissue in culture, and he identified that factor as the tripeptide glycyl-histidyl-lysine. The finding was published in Nature New Biology.

Work through the following two decades established the copper connection. The tripeptide was shown to bind copper(II) with high affinity, and the biological activities observed in culture were shown to depend on the complex rather than on the peptide alone. In 1988 a French group led by Francois-Xavier Maquart reported that GHK-Cu stimulated collagen synthesis in fibroblast cultures, which became the most reproduced finding in this literature. Subsequent work from the same group and others reported effects on glycosaminoglycan and decorin synthesis and on the balance between matrix metalloproteinases and their tissue inhibitors.

GHK is also generated endogenously rather than only circulating as a free species. The sequence occurs in collagen and in the matricellular protein SPARC, and proteolytic cleavage of those proteins during tissue injury has been proposed as the source of locally elevated GHK at wound sites. Reviews by the original discoverer report plasma GHK concentrations of roughly 200 nanograms per milliliter in young adults declining to roughly 80 nanograms per milliliter by the sixth decade, a figure widely repeated in the literature and worth attributing to its source rather than treating as independently established. A 2012 gene expression study using a public connectivity database reported that GHK exposure reversed a gene expression signature associated with emphysematous lung tissue destruction in cultured fibroblasts, which broadened interest beyond dermatology.

The free tripeptide has the sequence Gly-His-Lys, molecular formula C14H24N6O4, and an average molecular weight of approximately 340.4 g/mol, with CAS number 49557-75-7. The copper(II) complex has the formula C14H22CuN6O4, an approximate molecular weight of 403.9 g/mol, and CAS number 89030-95-5. Both numbers appear in supplier documentation for this product category, and researchers should confirm which species a certificate of analysis describes, because a mass specification written for the free peptide does not characterize the complex.

The coordination chemistry is what makes the peptide function as a carrier. Copper(II) is bound by the free amino terminus, by the imidazole nitrogen of the histidine side chain, and by the deprotonated backbone amide nitrogen, a coordination pattern closely related to the amino-terminal copper and nickel binding motif found in serum albumin. The lysine side chain does not participate directly in the metal coordination but contributes to the overall charge and solubility of the complex. The resulting geometry is square planar, and the blue color arises from the d-d electronic transition of the bound copper centered near 620 nanometers.

That color is a practical analytical handle. A GHK-Cu preparation that is white rather than blue is either the free peptide without copper or a complex that has lost its metal, and a solution that fades has undergone a change in copper coordination state. Either observation warrants discarding the material rather than proceeding. The affinity of GHK for copper is deliberately intermediate: high enough to prevent free copper in solution but low enough to permit exchange with albumin, which has higher affinity. A carrier that bound copper irreversibly would be a chelator, not a delivery molecule, and the distinction is central to how this compound is understood.

The best-supported mechanistic account runs through copper-dependent enzymes. Lysyl oxidase is a copper-requiring amine oxidase that oxidatively deaminates specific lysine and hydroxylysine residues in collagen and elastin to allysine, the reactive aldehyde that forms the covalent crosslinks giving those fibers their tensile properties. Without adequate copper, lysyl oxidase cannot function and crosslinking fails, which is the biochemical basis of the connective tissue abnormalities seen in copper deficiency states. Other copper-dependent enzymes include copper-zinc superoxide dismutase, cytochrome c oxidase in the respiratory chain, tyrosinase, and dopamine beta-hydroxylase.

Fibroblast culture work is the second pillar. Multiple laboratories have reported that GHK-Cu exposure increases synthesis of collagen, elastin, glycosaminoglycans, and the proteoglycan decorin in cultured dermal fibroblasts, and that it modulates the balance between matrix metalloproteinases and tissue inhibitors of metalloproteinases rather than simply suppressing matrix turnover. The reported pattern is one of altered remodeling rather than unidirectional matrix accumulation, which is a more interesting result than simple stimulation would be.

A third line of work concerns transcriptional effects. Gene expression profiling has reported that GHK exposure shifts expression of a large number of genes in cultured cells, with reported enrichment in categories relating to matrix remodeling, DNA repair, antioxidant response, and inflammatory signaling. Whether these represent direct transcriptional actions of the peptide, downstream consequences of restoring copper availability to copper-dependent enzymes, or a combination has not been resolved, and the distinction matters for interpreting the whole literature.

Additional reported activities include chemoattractant effects on macrophages and mast cells in wound models, modulation of transforming growth factor beta signaling, and antioxidant activity attributed in part to the copper-zinc superoxide dismutase connection. As with the other compounds in this library, these are associations observed in model systems.

What is established: the coordination chemistry is solid and independently verified. GHK binds copper(II) in a defined geometry with a measurable affinity, and the copper dependence of lysyl oxidase and the other cuproenzymes named above is textbook biochemistry. The fibroblast culture findings on collagen and matrix protein synthesis have been reproduced by laboratories independent of the original discoverer, which is a meaningful strength relative to several other compounds in this category.

What has limited human data: small human studies exist for topical cosmetic formulations containing the copper peptide, generally measuring skin appearance and related endpoints. These studies are typically small, of short duration, frequently industry-sponsored, and conducted on formulated topical products rather than on the raw compound. They establish that topical formulations have been evaluated in people. They do not establish systemic effects, do not address any other route, and should not be cited as clinical evidence in the sense that term carries in medicine.

What is animal-model or cell culture only: the wound remodeling literature, the gene expression profiling results, the reported anti-inflammatory and antioxidant effects, and the lung tissue signature work. There is no controlled human clinical trial of injectable or systemic GHK-Cu for any application, no published human pharmacokinetic characterization for that route, and no long-term human safety data.

One structural caveat and one chemical one deserve attention. Structurally, a substantial share of the review literature on GHK-Cu is authored by the compound's original discoverer, and while the primary fibroblast findings have independent support, readers should distinguish primary research from advocacy reviews when assessing the strength of a claim. Chemically, copper is a redox-active metal, and any experiment that introduces copper into a system introduces copper load as a variable, whether or not it is complexed. Appropriate copper-only and peptide-only controls are the difference between a result about GHK-Cu and a result about copper.

The lyophilized complex is stored at -20 C or below for long-term inventory, with 2 to 8 C acceptable for short-term working stock, kept desiccated and protected from light. The powder is hygroscopic, so vials should be equilibrated to room temperature before opening and closed again promptly. The characteristic blue color of the dry material should be noted on receipt as a first-pass identity check.

GHK-Cu dissolves readily in water, giving a blue solution. Diluent is added slowly down the vial wall, and the vial is swirled gently rather than vortexed. Buffer selection requires more thought than it does for ordinary peptides, because strong chelators will strip copper from the complex. Buffers containing EDTA are incompatible, and phosphate buffers at higher concentrations can also interact with copper coordination. Where the intact complex is the experimental subject, the buffer should be checked for chelating capacity before use rather than after an unexpected result.

Reconstituted solutions are held cold and protected from light and are aliquoted for single use. Color is the most informative stability indicator available for this compound: a solution that loses its blue tint has lost or altered its copper coordination and is no longer the material the experiment was designed around, regardless of what the peptide backbone is doing. Green or brown discoloration indicates copper oxidation state change or degradation and warrants discarding. Label aliquots with compound, lot, concentration, buffer composition, and preparation date, and record buffer composition specifically because of the chelation sensitivity described above.